SubscribeLogin
dermatologytimes.com image

News from dermatologytimes.com

We’ve assigned a rating of Unknown factuality to dermatologytimes.com. You can read more about how we’ve determined dermatologytimes.com’s credibility and reliability as a news source here: https://ground.news/rating-system.

Information about dermatologytimes.com

Where is dermatologytimes.com located?dermatologytimes.com's Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top dermatologytimes.com News

Nonsteroidal Topical OK'd for Atopic Dermatitis
FDA · United States

Nonsteroidal Topical OK'd for Atopic Dermatitis

100% Center coverage: 1 sources
(MedPage Today) -- The FDA approved tapinarof cream 1% (Vtama) for eczema in individuals ages 2 years and older, drugmaker Organon announced on Monday. Approval of the topical aryl hydrocarbon receptor agonist was supported by the pivotal ADORING...See the Story
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short Interest

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short Interest

100% Center coverage: 1 sources
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 23,530,000 shares, a decrease of 6.0% from the November 15th total of 25,020,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is currently 11.8 days.See the Story
MMRV Safety Assessed in Children on Methotrexate, Dupilumab
Vaccines

MMRV Safety Assessed in Children on Methotrexate, Dupilumab

TOPLINE: A retrospective analysis finds no adverse events (AEs) in children receiving a live attenuated vaccine against measles, mumps, rubella, and varicella (MMRV) while on dupilumab or methotrexate treatment, challenging current recommendations. METHODOLOGY: Researchers conducted a retrospective search of electronic medical records at a pediatric tertiary care center between 2017 and 2023, identifying patients who […]See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal